Lynne S. Brunner

Besifloxacin, a Novel Fluoroquinolone, Has Broad-Spectrum In Vitro Activity against Aerobic and Anaerobic Bacteria

Wolfgang Haas, Chris M. Pillar, Gary E. Zurenko et al. · Antimicrobial Agents and Chemotherapy · 2009 · 102 citations · Full text

Antibacterial Spectrum, Health Sciences, Antibiotics +15

Efficacy and Safety of Besifloxacin Ophthalmic Suspension 0.6% Compared with Moxifloxacin Ophthalmic Solution 0.5% for Treating Bacterial Conjunctivitis

Marguerite B. McDonald, Eugene Protzko, Lynne S. Brunner et al. · Ophthalmology · 2009 · 80 citations

Ocular Disease, Ophthalmology, Eye Health +7

Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis

Michael Tepedino, Warren Heller, Dale W. Usner et al. · Current Medical Research and Opinion · 2009 · 79 citations

Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study

Paul Karpecki, Michael DePaolis, Judy A. Hunter et al. · Clinical Therapeutics · 2009 · 77 citations

Ocular Disease, Ophthalmology, Safety Study +6